{
    "clinical_study": {
        "@rank": "116141", 
        "arm_group": [
            {
                "arm_group_label": "prednisone 50 mg tablet", 
                "arm_group_type": "Active Comparator", 
                "description": "This group included 15 patients who received prednisone (Delta-cortene Fort\u00ae, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening)  for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks."
            }, 
            {
                "arm_group_label": "Omega-3 capsules 1000 mg", 
                "arm_group_type": "Active Comparator", 
                "description": "This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months."
            }
        ], 
        "brief_summary": {
            "textblock": "This study was initiated to evaluate the potential of dietary supplementation of omega-3\n      for providing an inexpensive, safe and effective therapeutic agent for managing\n      atrophic/erosive lichen planus."
        }, 
        "brief_title": "The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Oral Lichen Planus", 
        "condition_browse": {
            "mesh_term": [
                "Lichen Planus", 
                "Lichen Planus, Oral"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Clinical diagnosis of OLP (Presence of painful and atrophic-erosive oral Lesions,\n             bilateral, mostly symmetrical lesions, presence of lace-like network of slightly\n             raised white lines).\n\n          2. Age between 30-60 years\n\n          3. Ability to complete the present clinical trial.\n\n        Exclusion Criteria:\n\n          1. Pregnant or breast feeding women (pregnancy test for women of child bearing age).\n\n          2. Lichenoid reactions caused by certain drugs or dental amalgam.\n\n          3. Therapy for  oral lichen planus (OLP) in the 6 months prior to the study.\n\n          4. Patient doesn't have hepatitis C [after the patients' medical histories were\n             recorded, the patients were given hepatic screening as published elsewhere. 2\n\n          5. Presence of candidiasis before treatment.\n\n          6. Patients with pre-existing diabetes or an initial random glucose level exceeding 200\n             mg/dL before initiating steroid therapy were excluded.\n\n          7. Hypertensive patients\n\n          8. Contraindications for corticosteroid use (immunodeficiency or severe heamatological\n             alterations)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106468", 
            "org_study_id": "Elgendy - 1"
        }, 
        "intervention": [
            {
                "arm_group_label": "prednisone 50 mg tablet", 
                "description": "This group included 15 patients who received prednisone (Delta-cortene Fort\u00ae, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening)  for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.", 
                "intervention_name": "Prednisone tablet 5mg", 
                "intervention_type": "Drug", 
                "other_name": "Delta-cortene Fort\u00ae, Lepetit, Carmano, Melano, Italy"
            }, 
            {
                "arm_group_label": "Omega-3 capsules 1000 mg", 
                "description": "This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.", 
                "intervention_name": "Omega-3 soft capsules 1000 mg", 
                "intervention_type": "Drug", 
                "other_name": "Super Omega; Technopharma, Cairo, Egypt"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Prednisone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Oral Lichen Planus", 
            "Corticosteroid", 
            "Omega -3"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo", 
                    "country": "Egypt"
                }, 
                "name": "October 6 University"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus and Improvement of Quality of Life: A Randomized, Double Blind, Controlled Study", 
        "overall_official": {
            "affiliation": "October 6 University", 
            "last_name": "Enas Elgendy, ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Egypt: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Improve quality of the life was recorded at baseline, 3 and 6 months after treatment.", 
            "measure": "Improve quality of the life (Oral Health Impact Profile)", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106468"
        }, 
        "responsible_party": {
            "investigator_affiliation": "October 6 University", 
            "investigator_full_name": "Enas Elgendy", 
            "investigator_title": "Lecuture, October 6 University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Size and types of the lesions were examined at the beginning of treatment, and then after 2 weeks, 1, 3, and 6 months of therapy.\nScore 5 = white striae with erosive area more than I cm Score 4 = white striae with erosive area less than 1 cm Score 3 = white striae with atrophic area more than I cm Score 2 = white striae with atrophic area less than I cm Score I =mild white striae, no erythematous area Score 0 = no lesion, normal mucosa", 
                "measure": "Size and types (atrophic/erosive) of the lesions", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Pain score was recorded at the beginning of treatment, and then after 2 weeks, 1, 3, and 6 months of therapy.\nScale 0: no pain: VAS=0 Scale 1: mild pain: 0< VAS\u22643.5 Scale 2: moderate pain: 3.5 <VAS\u22647 Scale 3: severe pain: 7< VAS\u226410.", 
                "measure": "Pain score (Visual analogue scale (VAS)),", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Recurrence within the following 3 months was recorded.", 
                "measure": "Recurrence of disease", 
                "safety_issue": "Yes", 
                "time_frame": "3 months"
            }
        ], 
        "source": "October 6 University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "October 6 University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}